Management of Cryptogenic Strokes by Percutaneous Closure of Interatrial Communications

Antonis S. Manolis, MD, FACC, FESC, FHRS

ABSTRACT

In patients with a cryptogenic stroke the prevalence of a patent foramen ovale (PFO) is increased to approximately 50% compared with a 25%-30% prevalence rate in the general population. This leads to a plausible assumption that a considerable number of strokes could potentially be attributed to a PFO, most likely due to paradoxical embolism. It is estimated that the risk for an embolic stroke due to the presence of a PFO may be 9-fold higher than that related to hypertension, diabetes or hypercholesterolemia. Furthermore, in the presence of an interatrial septal aneurysm (IASA), this risk may even be 30-fold higher. The management of patients with a cryptogenic stroke and a PFO is currently based on antithrombotic or anti-platelet therapy, however the recurrence rate remains high (4-25%), and this has led to the recommendation of percutaneous PFO closure, which is now effected via a simple and relatively safe technique, which appears to reduce recurrences to 0-5%. However, the studies which provide such favorable data are only retrospective, which means that we are in dire need of prospective randomized studies that compare the two therapeutic approaches, before the interventional method is more widely adopted.

In addition to cryptogenic stroke, the presence of a PFO has been also associated, among other conditions, with bouts of migraine and its percutaneous closure has been shown, albeit via retrospective and observational data, to eliminate or significantly improve this common condition. The only prospective randomized trial available (MIST trial) failed to show conclusively the superiority of PFO closure to medical treatment with regards to elimination of migraine.

Another large group of patients undergoing percutaneous closure of an interatrial communication are those with a secundum atrial septal defect (ASD). The majority of these patients, at least those having defects as large as 35-38 mm and an adequate rim to support a closure device, can now be successfully submitted to the percutaneous technique and thus avoid surgery. Certainly, these patients could also suffer from cryptogenic strokes and migraine, however, most of them usually require intervention because of hemodynamic reasons.

The technique of percutaneous closure of a PFO or an ASD performed by adult interventional cardiologists is indeed a relatively simple and swift procedure of right heart catheterization, carried out from the groin area via the femoral vein with use of local anesthesia. Complications related to the procedure are limited to ≤1-3.4%. Due to this paradigm of technological progress, a rapid growth of procedures of percutaneous closure of ASD and PFO has been noted over the last decade, particularly over the recent 4-5 years. Nevertheless, one has to resist in widely and hastily adopting such methods before further strong evidence becomes available via randomized prospective studies.
CRYPTOGENIC STROKES AND PATENT FORAMEN OVALE - PFO

Over the recent years, significant progress has been accomplished in the percutaneous management of endocardial communications, thus obviating the need for open heart surgery procedures. Among these, a rapid growth of procedures of percutaneous closure of atrial secundum defects (ASD) and patent foramen ovale (PFO) has been noted, particularly in young patients with cryptogenic strokes and/or migraine headaches.1-3

Cerebrovascular accidents or strokes are the third cause of death following cardiovascular events and cancer. It is estimated that approximately 750 000 strokes occur yearly in the USA, accounting for a 27% mortality rate. Among these, around 600 000 strokes are considered ischemic in origin and 10-40% of them are considered cryptogenic, i.e. of unknown cause or source.4,5 It is in this group of patients with a cryptogenic stroke that the prevalence of a PFO is found to be increased to approximately 50% compared with a 25%-30% prevalence rate in the general population,6-8 a fact that leads to a plausible assumption that 30000-120000 strokes could potentially be attributed to a PFO, most likely due to paradoxical embolism.9-13 It is estimated that the risk for an embolic stroke due to the presence of a PFO may be 9-fold higher than that related to hypertension, diabetes or hypercholesterolemia.11,12 Furthermore, in the presence of an interatrial septal aneurysm (IASA), this risk culminates to even a 30-fold increase.8 Magnetic resonance imaging (MRI), and not computed tomography (CT) scanning, is considered the most appropriate imaging technique to display the cerebral infarcts.14 In certain cases in the literature, thrombus has been “caught in the act”,15,16 i.e. straddling the PFO, in its passage from the right to the left circulation, necessitating surgery for its removal.

The diagnosis of a PFO demands a transesophageal echocardiography (TEE)17 study assisted by a “bubble study”, whereby a rapid injection of agitated saline or other contrast material via the antecubital vein can demonstrate the right-to-left passage of microbubbles of saline or contrast directly or after Valsalva maneuvering. An alternate method is a transcranial Doppler study, when the flow of the middle cerebral artery is disturbed from the right-to-left passage of microbubbles of the agitated saline or other contrast material again injected via the antecubital vein; of course, the right-to-left shunting is thus confirmed but the level of communication (atrial or ventricular or other) is not visualized with this technique. In cases where clinical suspicion is high (e.g. in presence of IASA) but these contrast studies are non-diagnostic or negative, repeat injections via the femoral vein may enhance the diagnosis, particularly in the presence of a Eustachian valve in the right atrium; less commonly, probing the inter-atrial septum with a catheter during right heart catheterization, e.g. during an electrophysiology study or an ablation procedure, can reveal a PFO.

The management of patients with a cryptogenic stroke (permanent or transient) and a PFO is currently based on antithrombotic or anti-platelet therapy,18,19 however the recurrence rate remains high (4-25%), a fact that has led to the recommendation of percutaneous PFO closure, which is now effected via a simple and relatively safe technique, which appears to reduce recurrences to 0-5%.20,21 However, the studies which provide such favorable data are only retrospective and data from prospective randomized studies that compare the two therapeutic approaches are still lacking. Recruitment of patients into such studies is slow, due to the fact that patients and physicians alike are reluctant to participate, since they intuitively opt for PFO closure as they consider it a more secure therapeutic modality rather than continuing medical therapy. Only though when such evidence-based data become available, will this matter of appropriate use of percutaneous PFO closure be finally and more definitively settled. All these notwithstanding, there has been an exponential increase of percutaneous procedures by a factor of 5- to 30-fold increase over the last decade, particularly over the recent 4-5 years.1,2 In our department, the program of percutaneous closures was started 4 years ago and counts around 55 procedures, all performed successfully; however, a hesitant referral pattern of such patients by their neurologists who usually first see and manage them is quite obvious and largely justified due to the incomplete data of evidence-based medicine, mainly related to randomized prospective studies, comparing this invasive approach with the alternative conservative approach with use of antithrombotic agents.

According with current guidelines of medical societies, such as the American College of Chest Physicians-ACCP, American Heart Association-AHA/American Stroke Association-ASA, and American Academy of Neurology - AAN, the evidence for PFO closure is still incomplete and mainly anti-platelet or anticoagulant therapy (the latter in presence of known deep vein thrombosis or thrombophilia) is recommended.22 They also encourage patient participation in prospective randomized study protocols, while they make mention (American Heart Association/American Stroke Association) for consideration of percutaneous closure in cases of recurrences despite medical therapy. However, when these options are put before a patient and his or her family, in the majority of cases an interventional approach is selected after a first stroke, rather than a life-long antithrombotic therapy, since very few settle with the idea of a remaining higher risk for recurrence. The data currently available from several comparative, albeit non-randomized, studies demonstrate a significant difference between the two approaches with regards to recurrences, indicating a much smaller percentage of recurrent stroke (0-4,9%) following PFO closure compared with the recurrence rate (3.8-12%) of
pharmacotherapy.\textsuperscript{3,18-21}

Certainly, one must emphasize that the PFO may simply serve in most cases as the passage gate of a right-sided thrombus to the systemic circulation leading to paradoxical embolism, and in very few one may suspect that there may be in situ thrombosis, particularly in large and long serpentine PFO tunnels,\textsuperscript{23} thus becoming imperative in most cases to search for the source or cause of thromboembolism, such as deep vein thrombosis (with use of Doppler ultrasound examination) or thrombophilia (e.g. associated with protein C or S deficiency, factor V Leiden, antiphospholipid antibody, etc.). If, indeed, such a thrombophilic state or thrombo-embolic source exists, percutaneous PFO closure does not cure or eliminate the problem, since a paradoxical embolic episode may be prevented, but there will remain a continuous risk of a serious pulmonary embolic episode, and thus the need for continuing anticoagulation therapy.\textsuperscript{3}

**PFO AND MIGRAINE**

Beyond the risk of a recurrent cryptogenic stroke due to paradoxical embolism, there are, of course, other reasons for PFO closure, such as diver’s disease,\textsuperscript{24,25} the syndrome of tachypnea and desaturation in upright position (tachypnea-orthodoxia),\textsuperscript{6} the “economy class” syndrome,\textsuperscript{10} the obstructive sleep apnea syndrome,\textsuperscript{26} the multiple infarct dementia,\textsuperscript{11} or even myocardial infarction due to paradoxical embolism,\textsuperscript{22} etc. Interestingly, after the fortuitous observation of reduction or elimination of migraine symptoms in patients with cryptogenic stroke undergoing percutaneous PFO closure, a heated discussion has ensued in the literature regarding the association of migraine with a PFO.\textsuperscript{9,27-40} One could attribute this association to substances such as serotonin, or to microthrombi crossing the PFO and bypassing the pulmonary circulation, a place of inactivation or neutralization, and these substances or other ones emanating from platelets produce vasoactive disturbances in the cerebral circulation with subsequent migrainous symptoms. Indeed, it is well known to neurologists that in a good number of patients afflicted with migraine, magnetic resonance imaging (MRI) of the brain discloses areas with “silent” infarcts, which could possibly be related to the presence of a PFO. Nevertheless, it is a fact that several publications report a significant reduction or even elimination of migraine symptoms after a percutaneous device closure of a PFO in an impressive number of cases ranging from 30\% to 80\%. These, of course, were all observational or retrospective data. However, there, indeed, seems to be an association of migraine with a PFO since the migraine incidence increases from \textasciitilde 12\% in the general population to 27-52\% in patients with cryptogenic stroke and PFO. On the other hand, the presence of a PFO increases from 27\% in the general population to 50\% in migraine sufferers, particularly those with typical migraine associated with an aura. Of course, the issue remains controversial in the absence of randomized prospective data associating migraine with a PFO and indicating a better outcome with percutaneous PFO closure. Indeed, the only prospective randomized trial available (the MIST trial)\textsuperscript{41} failed to show conclusively the superiority of PFO closure to medical treatment with regards to elimination of migraine in 147 patients randomized to a PFO closure or sham procedure. Nevertheless, a greater percentage (42\%) of patients improved amongst those receiving the device compared to those who did not (23\%). An argument has been put forth that that the procedure was carried out with a suboptimal device, but this remains to be proven.

**ATRIAL SECUNDUM DEFECT- ASD**

Another large group of patients undergoing percutaneous closure of an interatrial communication are those with an ASD. The majority of these patients, at least those having defects as large as 35-38 mm and an adequate rim to support a closure device, can now be successfully submitted to the percutaneous technique and thus avoid surgery.\textsuperscript{42-44} Certainly, these patients could also suffer from cryptogenic strokes and migraine, however, most of them usually require intervention because of hemodynamic reasons such as large right-to-left shunting (Qp/Qs \textasciitilde 1.5:1.0) leading to right ventricular dilation and dysfunction. Intervention has to occur.
PFO AND ASD CLOSURE

before pulmonary hypertension develops (with pulmonary pressure >70% systemic pressure) and pulmonary resistance increases excessively (beyond 5 units Wood/m²), all leading to reversal of flow (Eisenmenger syndrome). Symptoms attributed to ASD comprise easy fatiguability, general weakness, dyspnea on exertion and/or at rest, syncope or palpitations. Finally, atrial septal defect of the primum or sinus venosus type remain surgical diseases.

PERCUTANEOUS CLOSURE

The technique of percutaneous closure of a PFO or an ASD performed by adult interventional cardiologists is indeed a relatively simple and swift procedure of right heart catheterization, carried out from the groin area via the femoral vein with use of local anesthesia. This method is quite different from that employed by pediatric cardiologists, who use general anesthesia and guidance by TEE throughout the procedure. In contrast, in the adult catheterization laboratory the procedure is carried out with use of local anesthesia and is only guided by fluoroscopy and contrast material injection, occasionally aided by use of intracardiac echocardiography. First, one gets access to the left atrium via the PFO or the ASD with use of a long guidewire. The longest delay indeed relates to the time required to cross the interatrial communication, which occasionally may be tedious due to an elongated and serpentine tunnelous formation of a PFO. The latter is further facilitated with use of precurved or steerable catheters. After the passage of the wire to the left atrium, a guiding catheter is advanced over the wire and secured in place and through this catheter the closure device is introduced into the left atrium. The closure device has two disks joined with a central axis or trunk (Figure 1). One disk is deployed in the left atrium, pulled back to the PFO or ASD until it gets stacked, and then the second disk is deployed in the right atrium. Subsequently, contrast material is injected through the guide catheter to check the position and confirm the absence of right-to-left shunting. Then the closure device is released from the holding device and its position re-checked with a new contrast injection. The duration of the whole procedure takes approximately 10-15 minutes for the PFO closure. For the ASD closure, additional time is usually required, as there is need to make further measurements with use of a balloon to precisely size the defect and select the appropriate device, before initiating the insertion procedure (Figure 2).

The patient stays in the hospital for only 1-2 days. Pre-treatment with aspirin (100-325 mg/d) and clopidogrel (75 mg/d) is used for 3-5 days before the procedure. This antithrombotic regimen is continued for 3-6 months afterwards, which is until complete endothelialization of the device is accomplished and thus the thromboembolic risk is obviated. A bolus of heparin injection (50-100 u/kg) and 2-3 doses of prophylactic antibiotic are administered peri-procedurally. A new TEE exam is performed the next day to confirm proper device position. It is occasionally possible to observe some degree of interatrial shunting during this examination as each of the device’s disks is really a sieve, while full impermeability is achieved at 3-6 months with full device endothelialization. During this critical 3-6 month period, prophylactic antibiotic treatment is recommended in case of dental or other procedures.

Complications related to the procedure are limited to ≤1-3.4% and comprise mainly reversible problems at the site of access in the groin (bleeding or hematomas), but more serious adverse effects may occur, such as device dislodgement and embolization, cardiac tamponade, air embolism and atrial tachyarrhythmias. Occasionally, thromboembolic complications and late cardiac perforation from device erosion have rarely been reported.

NEW TECHNIQUES

Novel percutaneous closure systems promise a smaller device volume on the left side, easier device manipulation and complete communication closure with a safer technique and elimination of thromboembolic complications. Of course, the existing closure systems have already minimal or absent thromboembolic risk, especially if a lege artis technique is employed with avoidance of endocardial thrombi formation during use and manipulation of guide wires and catheters. New bioabsorbable devices are being tested, while novel methods of fusion of the two atrial membranes (primum and secundum

FIGURE 2. Fluoroscopic appearance (LAO projection) of an ASD closure device with the two disks held together with a thick trunk, which covers completely the atrial defect. Injection of contrast material in the right atrium shows the absence of right-to-left passage and thus the complete coverage and closure of the defect.
part of the interatrial septum) are under investigation with use of radiofrequency energy, but have only produced modest success to date, in hope to further perfect such techniques and thus obviate the need for foreign material implantation in the future.

CONCLUSION

As up to 25% of patients with a cryptogenic stroke may have a recurrence within 4 years of the first event despite antithrombotic pharmacotherapy and because the presence of a PFO represents a congenital defect which can be easily remedied, several experts believe that the percutaneous closure of the PFO should be the treatment of choice in patients with cryptogenic stroke and a PFO even after the first event. Over the last several years, there has been a great technological progress in percutaneous PFO devices and closure techniques. Nevertheless, one has to resist in widely and hastily adopting such methods before further strong evidence becomes available via randomized prospective studies. At the same time, attempts are continued in developing safer and more efficacious closure devices with fewer or no metallic elements or with bioabsorbable material. Ideally, physicians should be able to discern high risk patients before they develop their first stroke and thus prevent it by proceeding to percutaneous complete closure with use of a device made from material that conforms well to both sides of the atrial septum and has no risk of thrombosis, erosion, infection, or arrhythmias. Prospective randomized trials comparing pharmacotherapy to device closure are under way, but their completion is delayed and patient recruitment is difficult as the incidence of recurrent stroke is low in young patients. Meanwhile, as the occurrence of device complications is decreasing and simpler and safer and more reliable devices are developed, the threshold of percutaneous closure rather decreases, a fact that has become apparent in recent years from the exponentially increasing number of percutaneous interventions for PFO closure worldwide.1,2,47

REFERENCES

35. Tsimikas S. Transcatheter closure of patent foramen ovale for migraine prophylaxis: hope or hype? J Am Coll Cardiol 2005;45:496